Autres langues Adagene Inc.

Actions

ADAG

US0053291078

Temps Différé Nasdaq Autres places de cotation 17:33:43 03/07/2024			Varia. 5j.	Varia. 1 janv.
2,98 ^USD	-0,33 %		-0,67 %	+54,29 %

29/03	Adagene Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
29/03	Adagene Inc. annonce des changements au sein de son conseil d'administration	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Adagene to Present at Investor Conferences in June	22/05
Adagene : Entry into Sales Agreement - Form 6-K	29/03
Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update	29/03
Adagene Inc. Announces Board Changes	29/03
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board	07/03
Adagene Inc. Appoints Heinz-Josef Lenz to Scientific and Strategic Advisory Board	07/03
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	27/02
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024	27/02
ADRs Close Higher, Ambow Education Holding Ltd. Climbs 117.4%	16/02
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	09/02
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination	09/02
Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody	09/02
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	09/02
ADRs End Higher; The9 Climbs 16%	19/01
Adagene Reports Positive Data on Colorectal Cancer Treatment Combination	17/01
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	16/01
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)	16/01
Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium	16/01
ADRs End Lower; Aslan Pharmaceuticals Declines 38%	16/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Adagene Inc.

Actions

ADAG

US0053291078

Autres langues

Filtres